1 / 1
Tirzepatide is a groundbreaking synthetic peptide that functions as a dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It represents a new class of incretin-based therapies known as “twincretins”, offering enhanced metabolic control for patients with type 2 diabetes and obesity.
Our Tirzepatide API is produced through advanced chemical synthesis techniques, ensuring high purity, low impurity levels, and excellent batch-to-batch consistency. Unlike rDNA-derived peptides, our synthetic API is free from host cell proteins and DNA, significantly improving biosafety and regulatory compliance. The manufacturing process has been optimized for scale-up to meet growing global demand.
Tirzepatide works by simultaneously stimulating both GIP and GLP-1 receptors, providing complementary and synergistic effects:
Enhances insulin secretion and may improve insulin sensitivity.
Suppresses glucagon release, delays gastric emptying, and reduces appetite.
Combined activity leads to:
Tirzepatide has demonstrated unprecedented efficacy in multiple large-scale clinical trials (SURPASS & SURMOUNT series):
Tirzepatide is not only reshaping the treatment paradigm for type 2 diabetes but also emerging as a major therapeutic option for medical weight loss and metabolic syndrome.
Our Tirzepatide API guarantees:
